1. Interstitial Lung Disease Induced by Pazopanib Treatment
   Shotaro Ide et al, 2017, Intern. Med. CrossRef
2. Cyclodextrin polymers as nanocarriers for sorafenib
   Valentina Giglio et al, 2018, Invest New Drugs CrossRef
3. Anticancer therapy and lung injury: molecular mechanisms
   Li Li et al, 2018, Expert Review of Anticancer Therapy CrossRef
4. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma
   Kohei Kotani et al, 2019, Clin J Gastroenterol CrossRef
5. Sorafenib
   , 2015, Reactions Weekly CrossRef
6. Population-Based Observational Study of Adverse Drug Event-Related Mortality in the Super-Aged Society of Japan
   Tomoko Funahashi et al, 2021, Drug Saf CrossRef
7. Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.
   Takeshi Imakura et al, 2022, Intern Med CrossRef
8. Lenvatinib-induced severe interstitial pneumonia in a patient with hepatocellular carcinoma: A case report
   Yuki Ikeda et al, 2021, Kanzo CrossRef
9. Inhibitory Effects of Dioscoreae Rhizoma and Polygalae Radix Mixture Combined with 
Sorafenib in Hepatoma Xenografts Model
   Mi-Rae Shin et al, 2024, Pharmacognosy Magazine CrossRef